Oxford Pharmascience Group Plc | Medicines made better

 

Latest News

2013

17 December Press release post MHRA
04 December Oxford Pharmascience appoints Dipharma to produce its commercial scale 'Gastric Safe' Ibuprofen
26 November Aché launches new sugar free version of Inellare
13 November New USA Guidelines urge wider use of statins
11 November Oxford Pharmascience receives Innovation Award from pharma partner
06 November Holding(s) in Company
06 November Holding(s) in Company
05 November Holding(s) in Company
31 October £4 million Placing
21 October Oxford Pharmascience formulates "Gastric Safe" Ibuprofen tablet
17 October Holding(s) in Company
17 October Holding(s) in Company
17 October Holding(s) in Company
17 October Holding(s) in Company
17 October Change of shareholder ownership and change of Director
18 September Oxford Pharmascience publishes its interim results for the six months to 30 June 2013
02 August Oxford Pharmascience establishes Scientific Advisory Board
30 July Holding(s) in Company
25 July Holding(s) in Company
25 July Oxford Pharmascience signs option with UCL to explore further compounds
17 July Oxford Pharmascience appoints Head of Clinical Development
14 June Result of Annual General Meeting
04 June Oxford Pharmascience announces line extension for Brazil
31 May Holding(s) in Company
31 May Holding(s) in Company
28 May Holding(s) in Company
24 May Holding(s) in Company
24 May Holding(s) in Company
22 May Holding(s) in Company
08 May Oxford Pharmascience announces successful study indicating reduced gastric irritation for OXPzero™ ibuprofen and initiates Safer NSAIDs programme
22 March Holding(s) in Company
20 March Holding(s) in Company
20 March Oxford Pharmascience Group Plc results for the year ended 31 December 2012
19 March Result of General Meeting
27 February Placing and Notice of General Meeting
28 January Oxford Pharmascience completes initial formulation development for leading statins
18 January Director's interest - Grant of options